Progress and challenges in targeting the SARS-CoV-2 papain-like protease
SARS-CoV-2 is the causative agent of the COVID-19 pandemic. The approval of vaccines
and small-molecule antivirals is vital in combating the pandemic. The viral polymerase …
and small-molecule antivirals is vital in combating the pandemic. The viral polymerase …
Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China
L Yang, Z Wang - European journal of medicinal chemistry, 2023 - Elsevier
The ongoing COVID-19 pandemic has resulted in millions of deaths globally, highlighting
the need to develop potent prophylactic and therapeutic strategies against SARS-CoV-2 …
the need to develop potent prophylactic and therapeutic strategies against SARS-CoV-2 …
In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir
M Kiso, S Yamayoshi, S Iida, Y Furusawa… - Nature …, 2023 - nature.com
Ensitrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro or
Nsp5), is clinically useful against SARS-CoV-2 including its omicron variants. Since most …
Nsp5), is clinically useful against SARS-CoV-2 including its omicron variants. Since most …
The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir
D Jochmans, C Liu, K Donckers, A Stoycheva… - MBio, 2023 - Am Soc Microbiol
The SARS-CoV-2 main protease (3CLpro) has an indispensable role in the viral life cycle
and is a therapeutic target for the treatment of COVID-19. The potential of 3CLpro-inhibitors …
and is a therapeutic target for the treatment of COVID-19. The potential of 3CLpro-inhibitors …
In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir
M Kiso, Y Furusawa, R Uraki, M Imai… - Nature …, 2023 - nature.com
Nirmatrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro), is
clinically useful against infection with SARS-CoV-2 including its omicron variants. Since …
clinically useful against infection with SARS-CoV-2 including its omicron variants. Since …
Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants
Genetic variation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
resulted in the emergence and rapid spread of multiple variants throughout the pandemic, of …
resulted in the emergence and rapid spread of multiple variants throughout the pandemic, of …
Omicron genetic and clinical peculiarities that may overturn SARS-CoV-2 pandemic: a literature review
The Coronavirus disease 2019 (COVID-19) pandemic poses a great threat to global public
health. The original wild-type strain of severe acute respiratory syndrome coronavirus 2 …
health. The original wild-type strain of severe acute respiratory syndrome coronavirus 2 …
Genetic Surveillance of SARS-CoV-2 Mpro Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid
JT Lee, Q Yang, A Gribenko, BS Perrin Jr, Y Zhu… - Mbio, 2022 - Am Soc Microbiol
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to represent a
global health emergency as a highly transmissible, airborne virus. An important coronaviral …
global health emergency as a highly transmissible, airborne virus. An important coronaviral …
COVID‐19 in early 2023: Structure, replication mechanism, variants of SARS‐CoV‐2, diagnostic tests, and vaccine & drug development studies
Abstract Coronavirus Disease‐19 (COVID‐19) is an infectious disease caused by severe
acute respiratory syndrome‐coronaviruses‐2 (SARS‐CoV‐2), a highly pathogenic and …
acute respiratory syndrome‐coronaviruses‐2 (SARS‐CoV‐2), a highly pathogenic and …
Remdesivir: a review in COVID-19
HA Blair - Drugs, 2023 - Springer
Remdesivir (Veklury®), a nucleotide analogue prodrug with broad-spectrum antiviral activity,
is approved for the treatment of coronavirus disease 2019 (COVID-19), the illness caused by …
is approved for the treatment of coronavirus disease 2019 (COVID-19), the illness caused by …